Helix BioPharma (TSE:HBP) Share Price Passes Below 50-Day Moving Average – What’s Next?

Helix BioPharma Corp. (TSE:HBP)’s stock price passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of C$2.27 and traded as low as C$2.15. Helix BioPharma shares last traded at C$2.26, with a volume of 2,624 shares trading hands.

Helix BioPharma Trading Down 5.8%

The stock has a fifty day simple moving average of C$2.27 and a 200-day simple moving average of C$1.82. The company has a market capitalization of C$172.61 million, a PE ratio of -32.29 and a beta of 0.42.

Helix BioPharma (TSE:HBP) last issued its earnings results on Wednesday, October 29th. The biopharmaceutical company reported C($0.01) earnings per share for the quarter. The firm had revenue of C$0.31 million during the quarter. As a group, equities research analysts predict that Helix BioPharma Corp. will post -0.11 EPS for the current year.

About Helix BioPharma

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.